Health Condition 1: C399- Malignant neoplasm of lower respiratory tract, part unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Lung cancer cohort: Blood will be drawn from lung cancer patients before any therapy or surgery begins.
Control Intervention1: Healthy co
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria for lung cancer patients 1. Age equal to or above 18 years (both male and female). 2. Confirmed Diagnosis: Lung cancer diagnosis confirmed by tissue biopsy, with a report available. 3. Imaging and Blood Reports: Availability of CT and Complete Blood Count (CBC) reports. 4. No Prior Cancer Treatment: Patients who have not undergone chemotherapy, radiation therapy, or surgery before enrollment. Inclusion criteria for healthy controls 1.No History of Malignancy: Individuals with no known history of any type of cancer. 2.No Severe Comorbidities: Participants should not have severe comorbid conditions that could influence study outcomes. 3.Clinically asymptomatic for lung cancer. 4.No CT and biopsy are required for enrollment in this cohort.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for lung cancer patients: 1. Pediatric Patients: Lung cancer patients aged below 18 years. 2. History of Other Cancers Any history of previous malignancies. 3. Prior or Ongoing Treatment: Patients who are currently on active therapy (chemotherapy, radiation) or have undergone surgery for lung cancer. 4. Patients with unavailable CT and biopsy reports will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity, specificity, Precision Recall (PR) Curve, Area under the curve, negative predictive value, positive predictive valueTimepoint: At Baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the consistency and reliability of VarSee s performance across multiple clinical centersTimepoint: End of the study;To compare VarSee s diagnostic accuracy with standard clinical methodologiesTimepoint: At Baseline;To identify potential challenges, limitations, and areas for optimization in real-world clinical settingsTimepoint: Every 3 months;To analyze the computational efficiency, error rates, and overall robustness of VarSee s algorithmic framework, ensuring reliable and scalable performance under varying clinical conditionsTimepoint: End of the study | — |
Countries
India
Contacts
Public ContactDr Minit Shah
Tata Memorial Hospital, Mumbai
Outcome results
None listed